TrialSignal
Clinical trial intelligence report
Use of AMP to Improve Tissue Delivery of Adenosine
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 13, 2026
NCT ID
NCT00179010
Status
TERMINATED
Phase
PHASE1
Sponsor
Vanderbilt University Medical Center
Executive brief
Investment-Ready Snapshot
Adenosine and AMP are substances normally present in the body. Adenosine is also given for the treatment of some heart rhythm problems and may be used to reduce heart damage during heart attacks. The problem in using adenosine is that it is taken up by cells and, therefore, very little of the adenosine we give by vein or in the artery actually reaches the tissue. We propose to use AMP as a way to improve delivery of adenosine. AMP is inactive by itself, but is converted to adenosine in tissue. We hope that by giving AMP we will increase levels of adenosine in tissue. To see if this is true, we will give either adenosine or AMP into the forearm artery while we measure how much adenosine reaches the forearm tissue.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00179010
Indication
Ischemia
Modality
small molecule
Target
Adenosine, Adenosine Mono Phosphate (AMP)
Intervention
Adenosine, Adenosine Mono Phosphate (AMP)
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.